Cymab ApS: Financial statements 2023
CVR: 39859173
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Cymab ApS (CVR 39859173) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,206,027 and a net result of DKK -2,580,789 compared with DKK -1,541,246 the year before. Equity in the 2023 report amounted to DKK -8,023,830. The company had 2 employees in the financial year.
- Gross Profit
- DKK -1,206,027
- Profit/Loss
- DKK -2,580,789
- Equity
- DKK -8,023,830
- Total Assets
- DKK 5,555,579
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -1.2M | -2.6M | -8M | 2 |
| 2022 | 0 | -1.2M | -1.5M | -5.4M | 2 |
| 2021 | - | -567K | -943K | -3.9M | 1 |
| 2020 | 0 | -1.1M | -956K | -3M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Cymab ApS has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -1,541,246.
As of April 17, 2023, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of April 17, 2023, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of April 17, 2023, Mads Nikolaj Behrndt-Eriksen has joined the board of directors of Cymab ApS.
As of April 17, 2023, Johan Henrik Faber is registered as adm. dir. of Cymab ApS.
As of April 17, 2023, Stine Louise Reedtz Kjellev is registered as director of Cymab ApS.
As of April 17, 2023, Hans Heugh Wandall has stepped down as adm. dir. of Cymab ApS.
On April 17, 2023, the company changed its name from Ebumab ApS to Cymab ApS.
As of April 16, 2023, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of April 16, 2023, Thomas Dal Stenfeldt Batchelor has left the board of directors of Cymab ApS.
About Cymab ApS
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity in the 2025 report amounted to DKK -20,227,476.